451 related articles for article (PubMed ID: 16504983)
1. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
2. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
3. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
4. Management of rare diseases.
Walshe JM
QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334
[No Abstract] [Full Text] [Related]
5. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
6. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
7. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
8. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
9. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
10. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
[TBL] [Abstract][Full Text] [Related]
11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
12. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
13. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
14. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
15. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
16. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
17. Orphan drugs and orphan tests in the USA.
Thoene JG
Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
[No Abstract] [Full Text] [Related]
18. Our moral obligations in caring for patients with orphan cancers.
Fernandez CV
CMAJ; 2007 Jan; 176(3):297, 299. PubMed ID: 17261816
[No Abstract] [Full Text] [Related]
19. Jumpstarting research into neglected diseases.
Leslie M
Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
[TBL] [Abstract][Full Text] [Related]
20. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]